Gene Predictis
Gene Predictis is a Swiss precision medicine company.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| EUR | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 1 % | (8 %) | 4 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Gene Predictis is a Swiss company specializing in precision medicine, providing high-quality diagnostic tests and analyses. Authorized by the Federal Office of Public Health (FOPH) and Swissmedic, the company offers a range of COVID-19 tests, including PCR-based diagnostic tests and rapid tests, primarily for travel purposes. Clients include patients and the broader medical community, who rely on Gene Predictis for accurate and reliable test results. The company operates within the healthcare sector, focusing on precision medicine, which involves tailoring medical treatment to the individual characteristics of each patient. Gene Predictis adheres to international quality standards ISO 15189:2012 and ISO 17025:2017, ensuring the highest quality and confidentiality in their services. The business model revolves around providing specialized medical testing services, generating revenue through direct payments for tests, which must be made in cash. The company is committed to maintaining medical secrecy and patient confidentiality.
Keywords: precision medicine, diagnostic tests, COVID-19, PCR tests, rapid tests, Swissmedic, FOPH, ISO standards, healthcare, patient confidentiality.